What's on this Page
What is Ravulizumab
Ravulizumab is a long-acting intravenous monoclonal antibody, complement inhibitor indicated for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
The recommended adult dosing regimen for PNH and aHUS consists of a loading dose followed by maintenance dose every 8 weeks, offering an advantage over eculizumab, which is dosed every 2 weeks.
Brand Name
ULTOMIRIS
Indications
- hemolytic-uremic syndrome
- paroxysmal nocturnal hemoglobinuria (PNH)
Side Effects
- abdominal pain
- alopecia
- anemia
- anorexia
- antibody formation
- anxiety
- arthralgia
- back pain
- constipation
- cough
- diarrhea
- dizziness
- dyspnea
- fatigue
- fever
- headache
- hypertension
- hyperthermia
- hypokalemia
- hypotension
- infection
- infusion-related reactions
- intracranial bleeding
- iron deficiency
- lymphadenopathy
- meningococcal infection
- myalgia
- nausea
- peripheral edema
- pharyngitis
- rash
- rhinitis
- rhinorrhea
- vitamin D deficiency
- vomiting
- xerosis
Monitoring Parameters
- hemoglobin/hematocrit
- LDH
- platelet count
- serum creatinine
Contraindications
- breast-feeding
- children
- hemolysis
- infants
- infection
- meningococcal infection
- pregnancy
- thrombotic microangiopathy
- vaccination
Interactions
There are no drug interactions associated with Ravulizumab products.
